Gender Difference in Liver Enzymes in Newly Defined Subgroups of Diabetes Revealed by a Data-Driven Cluster Analysis

Abstract

Background Recently, a newly proposed data-driven approach for classifying diabetes has challenged the status quo of the classification of adult-onset patients with diabetes. This study investigated the association between liver injury and diabetes, classified by data-driven cluster analysis, as liver injury is a significant risk factor for diabetes.

Methods We enrolled 822 adult patients with newly diagnosed diabetes. Two-step cluster analysis was performed using six parameters, including age at diagnosis, body mass index, hemoglobin A1C, homoeostatic assessment model 2 estimates about insulin resistance (HOAM2-IR) and beta-cell function (HOMA2-B), and glutamic acid decarboxylase antibodies (GADA) positivity. Patients were allocated into five clusters. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity were compared as indicators of liver injury among clusters.

Results Serum ALT and AST activities were significantly different among clusters (P=0.002), even among those without GADA positivity (P=0.004). Patients with severe insulin-resistant diabetes (SIRD) and mild obesity-related diabetes (MOD) had a more severe liver injury. Gender dimorphism was also found for serum ALT and AST activities among subgroups. Female patients had better liver function than males with SIRD and MOD.

Conclusions We verified the feasibility of a newly proposed diabetes classification system and found robust and significant relationship and gender differences between serum ALT and AST activities and diabetes in some specific subgroups. Our findings indicate that more attention should be paid to diabetes subgroups when studying risk factors, indicators, or treatment in diabetic research.

Key words

cluster analysis - diabetes mellitus - liver diseases - gender difference

Publication History

Received: 06 December 2021
Received: 28 January 2022

Accepted: 07 March 2022

Article published online:
31 May 2022

• References

• 1 Rawshani A, Rawshani A, Franzen S. et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. New Engl J Med 2017; 376: 1407-1418
• 2 Wang L, Gao P, Zhang M. et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 2017; 317: 2515-2523
• 3 Ahlqvist E, Storm P, Karajamaki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369
• 4 Hsieh PS, Hsieh YJ. Impact of liver diseases on the development of type 2 diabetes mellitus. World J Gastroenterol 2011; 17: 5240-5245
• 5 Kaneko K, Yatsuya H, Li Y. et al. Association of gamma-glutamyl transferase and alanine aminotransferase with type 2 diabetes mellitus incidence in middle-aged Japanese men: 12-year follow up. J Diabetes Investig 2019; 10: 837-845
• 6 Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018; 41: S13-s27
• 7 Hu C, Jia W. Diabetes in China: Epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes 2018; 67: 3-11
• 8 Yang W, Lu J, Weng J. et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1101
• 9 Nazare JA, Smith JD, Borel AL. et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: The International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. Am J Clin Nutr 2012; 96: 714-726
• 10 Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006; 29: 1845-1850
• 11 Kelley DE, McKolanis TM, Hegazi RA. et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906-E916
• 12 Banerji MA, Buckley MC, Chaiken RL. et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995; 19: 846-850
• 13 Browning JD, Szczepaniak LS, Dobbins R. et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology (Baltimore, Md) 2004; 40: 1387-1395
• 14 Jimba S, Nakagami T, Takahashi M. et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-1145
• 15 Gholam PM, Flancbaum L, Machan JT. et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399-408
• 16 De Pergola G, Castellana F, Zupo R. et al. A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight. Sci Rep 2021; 16 11 24084
• 17 Forlani G, Di Bonito P, Mannucci E. et al. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Investig 2008; 31: 146-152
• 18 Dong MH, Bettencourt R, Barrett-Connor E. et al. Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PLoS One 2010; 8 5 e14254
• 19 Dong MH, Bettencourt R, Brenner DA. et al. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol 2012; 10: 285-290
• 20 Cho NH, Jang HC, Choi SH. et al. Abnormal liver function test predicts type 2 diabetes: A community-based prospective study. Diabetes Care 2007; 30: 2566-2568
• 21 Nguyen QM, Srinivasan SR, Xu JH. et al. Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the Bogalusa Heart Study. Diabetes Care 2011; 34: 2603-2607
• 22 Wang YL, Koh WP, Yuan JM. et al. Association between liver enzymes and incident type 2 diabetes in Singapore Chinese men and women. BMJ Open Diabetes Res Care 2016; 4: e000296
• 23 Ko SH, Baeg MK, Han KD. et al. Increased liver markers are associated with higher risk of type 2 diabetes. World J Gastroenterol 2015; 21: 7478-7487
• 24 Abbasi A, Bakker SJ, Corpeleijn E. et al. Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts. PloS One 2012; 7: e51496
• 25 Chen S, Guo X, Chen Y. et al. Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: A cross-sectional study from China. Postgrad Med 2016; 128: 770-776
• 26 Xu L, Jiang CQ, Schooling CM. et al. Liver enzymes as mediators of association between obesity and diabetes: The Guangzhou Biobank Cohort Study. Ann Epidemiol 2017; 27: 204-207
• 27 Hong NS, Kim JG, Lee YM. et al. Different associations between obesity and impaired fasting glucose depending on serum gamma-glutamyltransferase levels within normal range: A cross-sectional study. BMC Endocr Disord 2014; 14: 57
• 28 Gray B, Muhlhausler BS, Davies PS. et al. Liver enzymes but not free fatty acid levels predict markers of insulin sensitivity in overweight and obese, nondiabetic adults. Nutr Res 2013; 33: 781-788
• 29 Horvath S, Erhart W, Brosch M. et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A 2014; 111: 15538-15543
• 30 Pang Q, Zhang JY, Song SD. et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol 2015; 21: 1650-1662
• 31 Li L, Liu DW, Yan HY. et al. Obesity is an independent risk factor for nonalcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies. Obesity Rev 2016; 17: 510-519
• 32 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
• 33 Fazel Y, Koenig AB, Sayiner M. et al. Epidemiology and natural history of nonalcoholic fatty liver disease. Metabolism 2016; 65: 1017-1025
• 34 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019; 92: 82-97
• 35 Marchesini G, Brizi M, Morselli-Labate AM. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455
• 36 Sanyal AJ, Campbell-Sargent C, Mirshahi F. et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192
• 37 Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 2019; 1: 329-341
• 38 Brown MS, Goldstein JL. Selective versus total insulin resistance: A pathogenic paradox. Cell Metab 2008; 7: 95-96
• 39 Chakravarthy MV. N-T B A The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diab Metab 2020; 00: e00112
• 40 Malenica M, Prnjavorac B, Causevic A. et al. Use of databases for early recognition of risk of diabetic complication by analysis of liver enzymes in type 2 diabetes mellitus. Acta Inform Med 2016; 24: 90-93
• 41 Alonso-Magdalena P, Ropero AB, Carrera MP. et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PloS One 2008; 3: e2069
• 42 Ahmed-Sorour H, Bailey CJ. Role of ovarian hormones in the long-term control of glucose homeostasis, glycogen formation and gluconeogenesis. Ann Nutr Metab 1981; 25: 208-212
• 43 Wang J, Liang Q, Ji L. et al. Gender-related difference in liver injury induced by Dioscorea bulbifera L. rhizome in mice. Hum Exp Toxicol 2011; 30: 1333-1341